TScan Therapeutics (TCRX) Leases (2020 - 2025)
Historic Leases for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $59.4 million.
- TScan Therapeutics' Leases fell 34.37% to $59.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.4 million, marking a year-over-year decrease of 34.37%. This contributed to the annual value of $64.4 million for FY2024, which is 136.24% up from last year.
- Per TScan Therapeutics' latest filing, its Leases stood at $59.4 million for Q3 2025, which was down 34.37% from $61.1 million recorded in Q2 2025.
- TScan Therapeutics' Leases' 5-year high stood at $64.4 million during Q4 2024, with a 5-year trough of $4.4 million in Q3 2022.
- In the last 5 years, TScan Therapeutics' Leases had a median value of $59.3 million in 2022 and averaged $42.3 million.
- As far as peak fluctuations go, TScan Therapeutics' Leases crashed by 2507.72% in 2022, and later soared by 124017.86% in 2023.
- Quarter analysis of 5 years shows TScan Therapeutics' Leases stood at $5.5 million in 2021, then skyrocketed by 976.34% to $59.1 million in 2022, then rose by 7.43% to $63.5 million in 2023, then increased by 1.36% to $64.4 million in 2024, then fell by 7.64% to $59.4 million in 2025.
- Its Leases was $59.4 million in Q3 2025, compared to $61.1 million in Q2 2025 and $62.7 million in Q1 2025.